What Is Ozempic? Uses, Results, Side Effects & Cost

Mechanism

How Ozempic Works

Semaglutide is a long-acting analog of glucagon-like peptide-1 (GLP-1), an incretin hormone the gut releases after eating. It binds GLP-1 receptors in the pancreas, brain, and gastrointestinal tract.

Clinically this produces four effects: glucose-dependent insulin secretion, suppression of inappropriate glucagon, slowed gastric emptying, and reduced appetite via central satiety pathways in the hypothalamus and brainstem [6]. Patients report earlier fullness, smaller portions, and reduced cravings — particularly for highly palatable foods.

Because the molecule is long-acting, Ozempic is dosed once weekly subcutaneously in the abdomen, thigh, or upper arm. Steady-state levels are reached after 4–5 weeks of consistent dosing, which is why titration and patience matter more than the headline dose [1].

Clinical Evidence

Ozempic for Weight Loss: What the Research Shows

Ozempic is FDA-approved for type 2 diabetes, not weight loss — but its weight-loss effect is well-documented. In the SUSTAIN-6 cardiovascular outcomes trial, semaglutide reduced major adverse cardiovascular events by 26% versus placebo in adults with type 2 diabetes [3].

The clearest weight-loss data comes from the higher-dose semaglutide program (marketed as Wegovy). In STEP 1, adults without diabetes on 2.4 mg weekly lost an average of 14.9% of body weight at 68 weeks versus 2.4% on placebo [2]. SELECT later showed semaglutide 2.4 mg reduced major cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, independent of diabetes [4].

Most Ozempic prescriptions max out at 2 mg weekly, which produces less weight loss than Wegovy's 2.4 mg but is meaningful — typically 6–10% of body weight in real-world cohorts. The trajectory is gradual: the STEP 1 curve continued downward through roughly week 60 before plateauing.

Candidacy

Who Is a Candidate?

Ozempic is FDA-approved for adults with type 2 diabetes to improve glycemic control and reduce cardiovascular risk in those with established cardiovascular disease [1]. Off-label use for weight management is common in clinical practice but should be evaluated case-by-case by a physician.

Reasonable candidates include adults with BMI ≥30, or BMI ≥27 with at least one weight-related condition such as hypertension, dyslipidemia, prediabetes, sleep apnea, or PCOS. Patients with insulin resistance, hormonal weight gain, or metabolic syndrome often respond well.

Absolute contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN2), prior serious hypersensitivity reaction, and pregnancy [1]. Relative contraindications: history of pancreatitis, severe gastroparesis, active gallbladder disease, severe GERD, eating disorders, or a BMI in the normal range where benefit does not outweigh risk.

Safety

Side Effects & Safety

Most adverse effects are gastrointestinal and dose-related: nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux. Symptoms typically peak during dose escalation and improve with time, smaller meals, and adequate hydration [1].

Less common but important risks include gallbladder disease (cholelithiasis, cholecystitis), acute pancreatitis, acute kidney injury from dehydration, and rare reports of bowel obstruction, ileus, and severe gastroparesis. Semaglutide carries a boxed warning regarding rodent thyroid C-cell tumors; relevance to humans is unclear but the contraindication for MTC/MEN2 history is absolute [1].

Loss of lean body mass is a documented effect of any rapid weight loss. Estimates from GLP-1 trials suggest 25–40% of total weight lost may be lean mass without protective interventions. Adequate dietary protein (1.2–1.6 g/kg goal weight) and structured resistance training are essential — not optional.

Compounded semaglutide sold through telehealth and med-spas is not FDA-approved. The FDA has documented dosing errors, adverse events, and salt-form substitutions (semaglutide sodium, semaglutide acetate) that are not the same active ingredient as Ozempic [5]. This is why physician supervision is non-negotiable.

Compare

Ozempic vs. Wegovy vs. Mounjaro

All three are once-weekly injectables, but the indication, max dose, and weight-loss expectation differ:

• ·Ozempic (semaglutide, up to 2 mg): FDA-approved for type 2 diabetes; ~6–10% weight loss is typical at the 2 mg dose.
• ·Wegovy (semaglutide, 2.4 mg): FDA-approved for chronic weight management; ~14.9% mean weight loss at 68 weeks in STEP 1 [2].
• ·Mounjaro (tirzepatide, up to 15 mg): FDA-approved for type 2 diabetes; dual GIP/GLP-1 agonist, ~20–22.5% mean weight loss in the SURMOUNT-1 obesity program (where the same molecule is sold as Zepbound) [3].

See the full head-to-head at /hautemd/compare/ozempic-vs-mounjaro-vs-zepbound/.

Cost

How Much Does Ozempic Cost?

List price for Ozempic is roughly $936–$998 per month (Novo Nordisk, June 2026), with retail cash prices commonly $800–$1,100+ depending on pharmacy.

Novo Nordisk's direct-pay program (NovoCare Pharmacy) currently offers a self-pay path: $199/month for the first two fills at 0.25 mg and 0.5 mg (intro offer through June 30, 2026), then $349/month at 0.25–1 mg and $499/month at 2 mg. With commercial insurance plus the NovoCare Savings Card, eligible patients may pay as little as $25/month (government plans excluded). Medicare Part D covers Ozempic for diabetes indications only.

For the full pricing breakdown, the new oral semaglutide option, and how to think about long-term cost — see /hautemd/costs/ozempic-cost/. Pricing should be re-verified quarterly; manufacturer programs change frequently.

Haute MD Standard

Why Physician-Guided GLP-1 Treatment Matters

A 30-second telehealth visit and a monthly compounded vial is not weight-loss medicine — it is a script transaction. The difference matters because GLP-1 therapy reshapes appetite, body composition, and metabolic risk simultaneously, and any one of those can be mismanaged.

A physician-led GLP-1 program includes a baseline workup (CBC, comprehensive metabolic panel, HbA1c, lipid panel, TSH, hormone panel where indicated), body-composition assessment (DEXA or bioimpedance) at baseline and quarterly, individualized titration based on tolerability rather than a fixed calendar, nutrition therapy that protects lean mass, structured resistance training, and a maintenance plan for after the loss phase ends.

Haute MD physicians treat obesity as the chronic, relapsing disease it is — not a cosmetic shortcut. The goal is durable metabolic improvement, preserved muscle, and a long-term plan you can actually live on. That is the line between medicine and a med-spa subscription.